Steven Dubois, MD
Basic profileDana-Farber/Boston Children's Cancer and Blood Disorders Center
Steven Dubois is an Oncology physician affiliated with Dana-Farber/Boston Children's Cancer and Blood Disorders Center. OpenAlex indexes 520 publications with 18,178 citations (h-index 65); ClinicalTrials.gov lists 5 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Pediatric Hematology-Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
450 Brookline Ave
Dana-Farber Cancer Institute
Boston, MA 022155418
Telephone
617-632-5460Registry record last updated 1 Sept 2015.
Clinical trials
- Lurbinectedin in FET-Fused Tumors
Sponsor: Children's Hospital of Philadelphia
- Cabozantinib With Topotecan-Cyclophosphamide
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20252 payments
- EMD Serono Research & Development Institute, Inc.Program year20241 payment
- JAZZ PHARMACEUTICALS INC.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
3 NIH research awards on record, funded 2015–2023 per NIH RePORTER. The latest:
- Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Dana-Farber Cancer Inst
FY2023$347,922R01CA214912 - Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Dana-Farber Cancer Inst
FY2021$594,506R01CA214912 - Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Dana-Farber Cancer Inst
FY2020$310,299R01CA214912
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Journal of Clinical Medicine
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Rani George, MD, PhD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Suzanne Shusterman, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Yoav Binenbaum, MD, PhD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Natasha Archer, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”